key: cord-0947982-l5s8lx7c
authors: Machado, Álvaro; Lesort, Cécile; Gran, Franziska; Vilas Boas, Pedro; Arianayagam, Sanju; Frings, Verena
title: Journal Club
date: 2020-11-24
journal: Eur J Dermatol
DOI: 10.1684/ejd.2020.3821
sha: 39df01fa7fb2e7ca9525ff47d3f4f5d0c07b3bff
doc_id: 947982
cord_uid: l5s8lx7c

nan

The European Journal of Dermatology has recently remodelled "What's new this month?", replacing it with this now entitled "Journal Club" section. In this subdivision, readers will find concise information about recent, highly interesting publications, not only in this journal, but also in other prestigious journals of dermatology. Recently, the world faced the beginning of the SARS-CoV-2 pandemic and numerous papers were released in virtually all scientific areas. This huge load of novel information is vital so that this challenging situation may be addressed and contained -dermatology was no exception. Recently, Torres and Puig published a valuable article addressing the management of cutaneous immune-mediated diseases during the coronavirus disease 2019 (COVID-19) pandemic [1] . SARS-CoV-2 infection stimulates a host inflammatory response which in most cases leads to viral clearance. However, for reasons that are still unclear, in a subgroup of patients, the secondary immune response may be exaggerated. A so-called "cytokine storm" takes place, leading to inflammatory-induced lung injury and other complications [2] . Several cutaneous immune-mediated diseases, including psoriasis, atopic dermatitis, and hidradenitis suppurativa, are therapeutically managed with biologic and non-biologic immunosuppressive and immunomodulatory drugs. Most recommendations from dermatology societies [3] [4] [5] advise patients to discontinue or postpone immunosuppressive or biologic therapy in the event of COVID-19. However, there is no available evidence that supports discontinuation of biologic treatment for most patients simply because of the risk of infection [6] . Altogether, the available data on past and present outbreaks of coronavirus suggest that immunosuppressed patients are not at an increased risk of severe disease or increased complication rates compared to the general population, and that immunosuppressive and immunomodulatory drugs may even control the "cytokine storm" associated with a poorer outcome in these patients. It is generally recommended to withhold immunosuppressive or biologic treatment in patients with active COVID-19 infection. Special attention should be given to patients with obesity, cardiovascular disease or other risk factors such as chronic lung disease, asthma, and age older than 60 years. Dermatofibrosarcoma protuberans (DFSP) is a neoplasm which belongs to the fibroblastic/myofibroblastic category according to the 2013 World Health Organization Classification of Tumours of Soft Tissue and Bone [7] . While complete surgical excision with clear microscopic resection margins (R0) is the standard treatment for both primary and recurrent DFSP [8] , the delimitation of surgical margins may be challenging due to the subclinical extent of invasion. Accordingly, DFSP shows high local recurrence rates, especially when surgical margins are less than 2 cm [9] [10] [11] . Consequently, the best surgical treatment for DFSP appears to be micrographic surgery and related techniques [9, [12] [13] [14] [15] [16] . In this regard, the Tübinger Torte technique (TTT) -in summary, a Mohs-like technique which requires more time -allows complete 3D-histological evaluation of the excisional margins of the tumour [17, 18] . Cammarata and colleagues reported new insights for safety margins for DFSP, comparing wide local excision (WLE) and TTT, in a retrospective study of 17 patients [19] . The mean preoperative lesion size was 4.55±5.34 cm 2 . The mean final total excised area was 17.73±11.75 cm 2 for TTT and 53.65±15.57 cm 2 for WLE. The amount of preserved healthy tissue using the micrographic technique was significant; 69.15% (95% CI: 62.95-75.36) of healthy tissue was preserved using TTT. No recurrence or metastases were observed in any of the patients after a median followup period of 38.00±21 months. Although the study has some limitations (low number of patients and the lack of long-term follow-up data), the authors concluded that TTT remains a safe and effective treatment for DFSP patients, mainly when it is essential to spare tissue and in challenging locations. Basal cell carcinoma (BCC) is the most common nonmelanoma skin cancer (NMSC) [20] . Although surgery is the first-line therapy, some cases can progress to an advanced state, frequently requiring non-surgical approaches, such as cryotherapy, adjuvant radiotherapy, and targeted therapy [21] . Locally advanced BCC (laBCC) has always represented an uncommon, difficult-to-treat form of skin cancer, but approval of the Hedgehog inhibitor (HHI), vismodegib, in 2012 has provided an effective treatment for this subgroup of patients [22] . The approved dosage is 150 mg per day. Although this novel drug has been shown to be safe and effective, some adverse events (AEs) during treatment, such as muscle spasms, dysgeusia, and alopecia, have been described [23] . Several schemes of dose reduction during treatment have been proposed in order to increase patients' compliance and adherence to treatment [24, 25] . Nonetheless, the effect of prolonged use of low-dose vismodegib, including treatment after complete remission (CR) of laBCC has been achieved, has not been described. Scalvenzi et al. reported a single-centre, observational, retrospective study assessing long-term efficacy of a continuous treatment with a low dose of vismodegib (150 mg/daily, once weekly) in patients who achieved CR of the disease during a one-year follow-up period [26] . Fortytwo patients (35 males, seven females) with a median age of 75.2 years, and complete regression of their advanced BCC after treatment with vismodegib, were included. Of these, 27 (64%) patients received a once-weekly maintenance dosage of 150 mg vismodegib for one year, and 15 (36%) patients decided not to take the maintenance dosage due to severe AEs. Patients who continued to receive the low-dose vismodegib treatment did not present any BCC recurrence during the one-year follow-up period. Furthermore, no AEs were reported with the exception of mild dysgeusia in 48% (13/27) of patients and mild muscle pain in 29.6% (8/27). In the group of patients who discontinued treatment, a BCC recurrence rate of 26.6% (4/15 patients) was reported. The retrospective design of the study and the fact that the control arm comprised a small number of patients were considered limitations. In conclusion, these results demonstrate that the maintenance dose of vismodegib effectively eliminated skin tumour recurrence and reduced the severity of common adverse events, therefore increasing patient compliance.

Managing cutaneous immune-mediated diseases during the COVID-19 pandemic

Immune responses in COVID-19 and potential vaccines: lessons learned from SARS and MERS epidemic

Managing Your Practice Through the COVID-19 Outbreak

Statement On The Coronavirus (COVID-19) Outbreak

Comunicado del Grupo de Psoriasis de la AEDV Sobre la Pandemia por COVID-19. Academia Española de Dermatología y Venereología

Should patients stop their biologic treatment during the COVID-19 pandemic

WHO Classification of Tumours of Soft Tissue and Bone, 4 th Ed

Marges d'exérèse des dermatofibrosarcomes cervico-faciaux par technique de Slow-Mohs : étude clinique rétrospective sur 20 cas

S1 guidelines for dermatofibrosarcoma protuberans (DFSP) -update 2018

Dermatofibrosarcoma protuberans: Margins reduction using slow-Mohs micrographic surgery. Experience with 35 patients

Wide local excision vs

Mohs Tübingen technique in the treatment of dermatofibrosarcoma protuberans: a two-centre retrospective study and literature review

The efficacy of Mohs micrographic surgery over the traditional wide local excision surgery in the cure of dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans

Dermatofibrosarcoma protuberans: wide local excision vs. Mohs micrographic surgery

Efficacy of Mohs micrographic surgery for the treatment of dermatofibrosarcoma protuberans

Diagnosis and treatment of dermatofibrosarcoma protuberans. European consensus-based interdisciplinary guideline

Control of excisional margins by conventional histopathological techniques in the treatment of skin tumours. An alternative to Mohs' technique

Dermatofibrosarcome de Darier-Ferrand : traitement par la technique chirurgicale de Tübingen (31 cas)

Safety margins for dermatofibrosarcoma protuberans: a comparison between wide local excision and Mohs Tubingen technique

Vismodegib in patients with advanced basal cell carcinoma: primary analysis of STE-VIE, an international, open-label trial

Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma

Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, Phase 2 trial

Managing adverse effects by dose reduction during routine treatment of locally advanced basal cell carcinoma with the hedgehog inhibitor vismodegib: a singlecentre experience

Low-dose vismodegib as maintenance therapy after locally advanced basal cell carcinoma complete remission: high efficacy with minimal toxicity

Dermpath & Clinic: Where the shoe pinches -painful plantar plaque